Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From WuXi Biologics
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
While strong growth in China's immuno-oncology sector continued in the last quarter, the momentum appears to be slowing, affecting by multiple factors including intense competition in the sector and price cuts related to reimbursement listing, while regulatory authorities have already warned about what they see as the wasting of resources on "redundant" development activities.
China's Center for Drug Evaluation has issued fresh warnings that it will tighten reviews of anti-tumor drugs on the grounds that “redundant” development activities waste clinical resources.
Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.
- Contract Research Organization-CRO
- Large Molecule